Top Story

Undiagnosed HBV, HCV, HIV prevalent in newly diagnosed cancer cases

January 17, 2019
FDA News

FDA approves Cabometyx for treatment-experienced patients with HCC

January 15, 2019
Exelixis has announced it has received FDA approval for Cabometyx to treat patients with hepatocellular carcinoma who previously underwent treatment with Nexavar…
In the Journals

Regular vigorous exercise reduces liver cancer risk

January 3, 2019
Regular vigorous physical activity reduced the risk for hepatocellular carcinoma by approximately 45%, according to recently published data. “The distribution of…

Oncimmune expands access to cancer risk lung, liver blood tests

December 29, 2018
Oncimmune Holdings entered into an agreement with America’s Choice Provider Network to expand access to the company’s EarlyCDT-Lung and EarlyCDT-Liver blood…
More Headlines »

Risky Business: Prophylaxis and Treatment of Cytomegalovirus in the Transplantation Setting

This activity is supported by educational grants from Merck & Co., Inc. and Shire.

Cytomegalovirus (CMV) is a common herpes virus that affects 50% to 80% of the US population. Disease from reactivation…
More »
GI Bookshelf

Question 28: I Have A Patient With Biliary-Type Pain, But No Other Evidence Of Bile Duct Disease (Normal Diameter Duct On Ultrasound, Normal Liver Function Tests). How Should Such A Patient Be Managed?

From Curbside Consultation in Endoscopy: 49 Clinical Questions, Second Edition
More »
Meeting News

Exact Sciences expands noninvasive cancer testing in the GI space

June 11, 2018
More »